TerminatedNCT00852059

Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA)

Medication studyAges 6–17Germany

The study in practice

Understand this study

Who could participate?

Listed age limits: 6 years to 17 years.

Listed locations: MainzSee all locations and recruitment
Study phase: Phase 4

Get this study by email

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMarch 2009

Recruitment status: Terminated
Enrollment listed in the registry: 32
Sponsor: Prof. Huss
Sponsor type: Individual investigator
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: Germany
Age range: From 6 Years to 17 Years
Official registry ID: NCT00852059
Official title: Show the full official title
Effect of Methylphenidate Formulation on ADHD-patients' Adherence to Medical Treatment. A Comparison of Medikinet Retard® (ER) Once Daily and Medikinet® (IR) Twice Daily in Children and Adolescents Diagnosed With ADHD

Recruitment & locations

Terminated

Mainz

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Prof. Huss.

Does this study involve medication?

Yes. The study involves medication, including Immediate release methylphenidate (Medikinet®) and Extended release methylphenidate (Medikinet retard®).

Who can participate?

Listed age limits: 6 years to 17 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies